Literature DB >> 2901964

Cyclic AMP-mediated alteration of the CD2 activation process in human T lymphocytes. Preferential inhibition of the phosphoinositide cycle-related transduction pathway.

G Bismuth1, I Theodorou, H Gouy, S Le Gouvello, A Bernard, P Debré.   

Abstract

Activation of human T lymphocytes via the CD2 molecule produces an enhanced turnover of phosphatidylinositol (PI) cycle-related phospholipids accompanied by the increased production of diacylglycerol (DG) and phosphorylated derivatives of inositol (IP). In this report we demonstrate that increased levels of intracellular cyclic AMP induced in human T lymphocytes by prostaglandin E2 or dibutyryl cAMP antagonize these early biochemical events of the CD2 activation process. Thus, a substantial inhibition of the CD2-induced increase in 32P-phosphatidic acid and 32P-PI values is observed. In parallel, both the DG production and the IP release triggered by the CD2 signal are strongly reduced contrasting with an almost conserved Ca2+ response. We also report here that cAMP does inhibit the CD2-induced proliferation in a dose-dependent manner while the proliferation generated independently of DG and IP production by a combination of Ca2+ ionophore A23187 and 12-O-tetradecanoylphorbol 13-acetate is not affected. These results therefore suggest that (a) intracellular cAMP levels may participate in the regulation of the PI cycle-related transduction pathway involved in the activation process of human T lymphocytes via the CD2 molecule; (b) the observed cAMP-mediated functional inhibitory effects are mainly related to an alteration of this cellular transduction signal; and (c) considering the putative critical second messenger role in the T cell proliferative response of DG and IP, respectively thought to activate the protein kinase C and to raise the intracellular free Ca2+, the lowering of DG production may be the key event responsible for this cAMP-mediated effect.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901964     DOI: 10.1002/eji.1830180908

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Cyclic AMP suppresses interleukin-5 synthesis by human helper T cells via the downregulation of the calcium mobilization pathway.

Authors:  O Kaminuma; A Mori; K Ogawa; H Kikkawa; A Nakata; K Ikezawa; H Okudaira
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Time-course changes in content and fatty acid composition of phosphatidic acid from rat thymocytes during concanavalin A stimulation.

Authors:  S el Bawab; O Macovschi; M Lagarde; A F Prigent
Journal:  Biochem J       Date:  1995-05-15       Impact factor: 3.857

3.  Ca(2+)-induced Ca2+ release amplifies the Ca2+ response elicited by inositol trisphosphate in macrophages.

Authors:  C Randriamampita; G Bismuth; A Trautmann
Journal:  Cell Regul       Date:  1991-07

4.  Inhibition of anti-CD3 monoclonal antibody-induced T-cell proliferation by dexamethasone, isoproterenol, or prostaglandin E2 either alone or in combination.

Authors:  L Elliott; W Brooks; T Roszman
Journal:  Cell Mol Neurobiol       Date:  1992-10       Impact factor: 5.046

5.  Intracellular mediators regulate CD2 lateral diffusion and cytoplasmic Ca2+ mobilization upon CD2-mediated T cell activation.

Authors:  S J Liu; W C Hahn; B E Bierer; D E Golan
Journal:  Biophys J       Date:  1995-02       Impact factor: 4.033

6.  Human immunodeficiency virus-1 glycoproteins gp120 and gp160 specifically inhibit the CD3/T cell-antigen receptor phosphoinositide transduction pathway.

Authors:  D Cefai; P Debre; M Kaczorek; T Idziorek; B Autran; G Bismuth
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

7.  The influence of intracellular cAMP on T cell proliferation.

Authors:  M Li; J Yang; Y N Hu; X T Ye; W X Ye
Journal:  J Tongji Med Univ       Date:  1995

8.  Tyrosine phosphorylation and association with phospholipase C gamma-1 of the GAP-associated 62-kD protein after CD2 stimulation of Jurkat T cell.

Authors:  P Hubert; P Debré; L Boumsell; G Bismuth
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.